Philippe Busque's most recent trade in Cytek BioSciences Inc was a trade of 5,551 Common Stock done . Disclosure was reported to the exchange on May 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 5,551 | 44,890 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 5,551 | 127,675 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 2,416 | 39,959 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 2,416 | 41,089 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 1,473 | 37,921 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 1,473 | 16,209 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 1,424 | 43,466 | - | 3.5 | 5,055 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 1,024 | 5,641 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 1,024 | 36,711 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 620 | 39,339 | - | 3.6 | 2,201 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 378 | 37,543 | - | 3.6 | 1,342 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 263 | 36,448 | - | 3.6 | 934 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 133,226 | 133,226 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 70,665 | 70,665 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 4,833 | 43,505 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 4,833 | 37,183 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,946 | 33,262 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,946 | 17,682 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,049 | 6,665 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,049 | 30,951 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 1,496 | 35,687 | - | 4.2 | 6,328 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 912 | 32,350 | - | 4.2 | 3,858 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 635 | 30,316 | - | 4.2 | 2,686 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 3,625 | 29,829 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 3,625 | 48,338 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 2,210 | 26,769 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 2,210 | 20,628 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 1,536 | 24,952 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 1,536 | 8,714 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 927 | 28,902 | - | 5.5 | 5,126 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 565 | 26,204 | - | 5.5 | 3,124 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 393 | 24,559 | - | 5.5 | 2,173 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 3,625 | 24,828 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 3,625 | 51,963 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 2,210 | 22,838 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 2,210 | 22,064 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,536 | 10,250 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,536 | 20,453 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 1,412 | 23,416 | - | 4.1 | 5,733 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 861 | 21,203 | - | 4.1 | 3,496 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 599 | 19,854 | - | 4.1 | 2,432 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 2,416 | 19,859 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 2,416 | 55,588 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,473 | 18,017 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,473 | 25,048 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,024 | 16,943 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,024 | 11,786 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 942 | 18,917 | - | 2.7 | 2,534 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 574 | 17,443 | - | 2.7 | 1,544 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 399 | 16,544 | - | 2.7 | 1,073 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,946 | 17,067 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,946 | 26,521 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,049 | 14,920 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,049 | 12,810 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 1,148 | 15,919 | - | 4.4 | 5,005 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 799 | 14,121 | - | 4.4 | 3,484 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 91,911 | 91,911 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 58,004 | 58,004 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,210 | 29,467 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 2,210 | 13,732 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,536 | 14,859 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,536 | 12,121 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 861 | 12,871 | - | 6.0 | 5,192 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 599 | 11,522 | - | 6.0 | 3,612 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 2,210 | 31,677 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 2,210 | 11,446 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,536 | 9,835 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,536 | 16,395 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 861 | 10,585 | - | 5.5 | 4,761 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 599 | 9,236 | - | 5.5 | 3,312 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,659 | 17,931 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 6,659 | 9,994 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 2,594 | 7,400 | - | 6.0 | 15,460 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,473 | 33,887 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,473 | 8,873 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 574 | 8,299 | - | 6.0 | 3,421 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 5,464 | 0 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 5,464 | 5,464 | - | - | Common Stock | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.70 per share. | 20 Mar 2024 | 2,129 | 3,335 | - | 6.7 | 14,264 | Common Stock |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 52,631 | 52,631 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Philippe Busque | SVP, GLOBAL SALES AND SERVICES | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 35,360 | 35,360 | - | - | Restricted Stock Units |